Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 plus Adebrelimab in Early/Locally Advanced HR-neg/low HER2-low Breast Cancer
NCT06592625Phase 2Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Sep 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan in breast cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: total Pathological Complete Response at 18 weeks. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06592625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592625.